Detalhe da pesquisa
1.
Class A capsid assembly modulator apoptotic elimination of hepatocytes with high HBV core antigen level in vivo is dependent on de novo core protein translation.
J Virol
; 98(3): e0150223, 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315015
2.
Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells.
Antimicrob Agents Chemother
; 62(4)2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439958
3.
The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.
Antimicrob Agents Chemother
; 61(5)2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28193653
4.
A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro.
Antimicrob Agents Chemother
; 60(9): 5504-14, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27381402
5.
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Liver Int
; 36(4): 505-14, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26519669
6.
Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
J Gastroenterol Hepatol
; 31(10): 1757-1765, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26992248
7.
A novel immuno-competitive capture mass spectrometry strategy for protein-protein interaction profiling reveals that LATS kinases regulate HCV replication through NS5A phosphorylation.
Mol Cell Proteomics
; 13(11): 3040-8, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25044019
8.
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
J Hepatol
; 62(2): 294-302, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25239078
9.
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
Liver Int
; 35(1): 108-19, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24517252
10.
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Liver Int
; 35(1): 79-89, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24814388
11.
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
J Infect Dis
; 209(5): 668-75, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24154738
12.
Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir.
Antimicrob Agents Chemother
; 58(6): 3105-14, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24637689
13.
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Antimicrob Agents Chemother
; 58(2): 1136-45, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24295986
14.
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Gastroenterology
; 145(4): 790-800.e3, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811112
15.
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
Hepatology
; 58(2): 514-23, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23359491
16.
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Hepatology
; 58(2): 524-37, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23348636
17.
mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model.
Vaccines (Basel)
; 12(3)2024 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38543871
18.
Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model.
Viruses
; 16(3)2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38543713
19.
Sustained Liver HBsAg Loss and Clonal T- and B-Cell Expansion upon Therapeutic DNA Vaccination Require Low HBsAg Levels.
Vaccines (Basel)
; 11(12)2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38140229
20.
Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
Antimicrob Agents Chemother
; 56(1): 271-9, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22064535